The pathogenesis of mucosal inflammation in murine models of inflammatory bowel disease and Crohn disease

Annals of Internal Medicine

Volumn 128, Issue 10, 1998, Pages 848-856

  Strober, Warren ^a   Lúdvíksson, Björn R ^a   Fuss, Ivan J ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 2; TRANSFORMING GROWTH FACTOR BETA; TRINITROBENZENESULFONIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; CONFERENCE PAPER; CROHN DISEASE; IMMUNOMODULATION; IMMUNOPATHOGENESIS; INTESTINE MUCOSA; MOUSE; MUCOSA INFLAMMATION; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE;

EID: 0032524131     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-128-10-199805150-00009     Document Type: Conference Paper

References (62)

1. Abbas AK, Murphy KM, Sher A. Functional diversity of helper T lymphocytes. Nature. 1996;383:787-93.
2. + lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Crohn's disease LP cells manifest increased secretion of IFN-γ, whereas ulcerative colitis LP cells manifest increased secretion of IL-5. J Immunol. 1996;157:1261-70.
3. Parronchi P, Romagnani P, Annunziato F, Sampognaro S, Becchio A, Giannarini L, et al. Type 1 T-helper cell predominance and interleukin-12 expression in the gut of patients with Crohn's disease. Am J Pathol. 1997; 150:823-32.
4. Stokkers PC, Camoglio L, van Deventer SJ. Tumor necrosis factor (TNF) in inflammatory bowel disease: gene polymorphisms, animal models, and potential for anti-TNF therapy. J Inflamm. 1995-96;47:97-103.
5. Neurath MF, Fuss IJ, Kelsall BL, Stüber E, Strober W. Antibodies to interleukin 12 abrogate established experimental colitis in mice. J Exp Med. 1995;182:1281-90.
6. Sadlack B, Merz H, Schorle H, Schimpl A, Feller AC, Horak I. Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene. Cell. 1993;75: 253-61.
7. Ehrhardt RO, Lúdvíksson BR, Gray B, Neurath MF, Strober W. Induction and prevention of colonie inflammation in IL-2-deficient mice. J Immunol. 1997;158:566-73.
8. Kühn RJ, Löhler J, Rennick D, Rajewsky K, Müller W. Interleukin-10-deficient mice develop chronic enterocolitis. Cell. 1993;75:263-74.
9. + T cells. Immunity. 1994;1:553-62.
10. Riddell RH. Pathology of idiopathic inflammatory bowel disease. In: Kirsner JB, Shorter RG, eds. Inflammatory Bowel Disease. 3d ed. Philadelphia: Lea & Febiger; 1988:329-50.
11. Schmitz-Moormann P, Becker H. Histological studies on the formal pathogenesis of the epithelioid cell granuloma in Crohn's disease. In: Pena AS, Weterman IT, Booth CC, Strober W, eds. Recent Advances in Crohn's Disease. The Hague: Martinus Nijhoff; 1981:76-9.
12. Geller SA. Pathology of inflammatory bowel disease: a critical appraisal in diagnosis and management. In: Targan SR, Shanahan F, eds. Inflammatory Bowel Disease: From Bench to Bedside. Baltimore: Williams & Wilkins; 1994: 336-51.
13. Podolsky DK. Inflammatory bowel disease (1). N Engl J Med. 1991;325:928-37.
14. Plevy SE, Targan SR, Yang H, Fernandez D, Rotter J, Toyoda H. Tumor necrosis factor microsatellites define a Crohn's disease-associated haplotype on chromosome 6. Gastroenterology. 1996;110:1053-60.
15. Satsangi J, Parkes M, Louis E, Hashimoto L, Kato N, Welsh K, et al. Two-stage genome-wide search in inflammatory bowel disease provides evidence for susceptibility loci on chromosomes 3, 7, and 12. Nat Genet. 1996; 14:199-202.
16. Ohmen JD, Yang HY, Yamamoto KK, Zhao HY, Ma Y, Bentley LG, et al. Susceptibility locus for inflammatory bowel disease on chromosome 16 have a role in Crohn's disease, but not in ulcerative colitis. Hum Mol Genet. 1996;5:1679-83.
17. Whelan G, Farmer RG, Fazio VW, Goormastic M. Recurrence after surgery in Crohn's disease. Relationship to location of disease (clinical pattern) and surgical indication. Gastroenterology. 1985;88:1826-33.
18. Sachar DB. The problem of postoperative recurrence of Crohn's disease. Med Clin North Am. 1990;74:183-8.
19. Mosmann TR, Coffmann RL. Different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol. 1989;7:145-73.
20. Boirivant M, Fuss IJ, Fiocchi C, Klein JS, Strong SA, Strober W. Hypoproliferative human lamina propria T cells retain the capacity to secrete lymphokines when stimulated via CD2/CD28 signaling pathways. Proc Assoc Am Physicians. 1996;108:55-67.
21. Targan S, Deem R, Liu M, Wang S, Nel A. Definition of a lamina propria T cell responsive state. Enhanced cytokine responsiveness of T cells stimulated through the CD2 pathway. J Immunol. 1995;154:664-75.
22. Breese E, Braegger CP, Corrigan O, Walker-Smith JA, MacDonald TT. Interleukin-2- and interferon-γ-secreting T cells in normal and diseased human intestinal mucosa. Immunology. 1993;78:127-31.
23. West GA, Matsuura T, Levine AD, Klein JS, Fiocchi C. Interleukin 4 in inflammatory bowel disease and mucosal immune reactivity. Gastroenterology. 1996;110:1683-95.
24. + T cells exhibiting an unbalanced Th1-type T cell cytokine pattern. Reversal with IL-10. J Immunol. 1998;160:3602-9.
25. Moller DR, Forman JD, Liu MC, Noble PW, Greenlee BM, Vyas P, et al. Enhanced expression of IL-12 associated with Th1 cytokine profiles in active pulmonary sarcoidosis. J Immunol. 1996;156:4952-60.
26. Weyand CM, Hicok KC, Hunder GG, Goronzy JJ. Tissue cytokine patterns in patients with polymyalgia rheumatica and giant cell arteritis. Ann Intern Med. 1994;121:484-91.
27. Kindler V, Sappino AP, Grau GE, Piguet PF, Vassalli P. The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection. Cell. 1989;56:731-40.
28. Orme IM, Roberts AD, Griffin JP, Abrams JS. Cytokine secretion by CD4 T lymphocytes acquired in response to tuberculosis infection. J Immunol. 1993;151:518-25.
29. Coers W, Brouwer E, Vos JT, Chand A, Huitema S, Heeringa P, et al. Podocyte expression of MHC class I and II and intercellular adhesion molecule-1 (ICAM-1) in experimental pauci-immune crescentic glomerulonephritis. Clin Exp Immunol. 1994;98:279-85.
30. Trinchieri G. Interleukin-12: a cytokine produced by antigen-presenting cells with immunoregulatory functions in the generation of T-helper cells type 1 and cytotoxic lymphocytes. Blood. 1994;84:4008-27.
31. Monteleone G, Biancone L, Marasco R, Morrone G, Marasco O, Luzza F, et al. Interleukin 12 is expressed and actively released by Crohn's disease intestinal lamina propria mononuclear cells. Gastroenterology. 1997;112: 1169-78.
32. Brynskov J, Nielsen OH, Ahnfelt-Ronne I, Bendtzen K. Cytokines (immunoinflammatory hormones) and their natural regulation in inflammatory bowel disease (Crohn's disease and ulcerative colitis): a review. Dig Dis. 1994; 12:290-304.
33. Ueta C, Kawasumi H, Fujiwara H, Miyagawa T, Kida H, Ohmoto Y, et al. Interleukin-12 activates human gamma delta T cells: synergistic effect of tumor necrosis factor-α. Eur J Immunol. 1996;26:3066-73.
34. + T cells and proinflammatory Th1-type cytokines. J Immunol. 1997;158:1068-72.
35. + T cells in inflammatory bowel disease. Gastroenterology. 1991;101:1594-605.
36. Matsuura T, West GA, Youngman KR, Klein JB, Fiocchi C. Immune activation genes in inflammatory bowel disease. Gastroenterology. 1993;104: 448-58.
37. De Waal Malefyt R, Abrams J, Bennett B, Figdor CG, de Vries JE. Interleukin 10 (IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. J Exp Med. 1991;174: 1209-20.
38. Romagnani S. Induction of TH1 and TH2 response: a key role for the "natural" immune response? Immunol Today. 1992;13:379-81.
39. Massague J. The transforming growth factor-β family. Annu Rev Cell Biol. 1990;6:597-641.
40. Ludviksson BR, Ehrhardt RO, Strober W. TGF-β production regulates the development of the 2,4,6-trinitrophenol-conjugated keyhole limpet hemocyanin-induced colonie inflammation in IL-2-deficient mice. J Immunol. 1997; 159:3622-8.
41. Neurath MF, Fuss IJ, Kelsall BL, Presky D, Waegell W, Strober W. Experimental granulomatous colitis in mice is abrogated by induction of TGF-β-mediated oral tolerance. J Exp Med. 1996;183:2605-16.
42. Miller A, Lider O, Roberts AB, Sporn MB, Weiner HL. Suppressor T cells generated by oral tolerization to myelin basic protein suppress both in vitro and in vivo immune responses by the release of transforming growth factor β after antigen-specific triggering. Proc Natl Acad Sci U S A. 1992;89:421-5.
43. Khoury SJ, Hancock WW, Weiner HL. Oral tolerance to myelin basic protein and natural recovery from experimental autoimmune encephalomyelitis are associated with downregulation of inflammatory cytokines and differential upregulation of transforming growth factor β, interleukin 4, and prostaglandin E expression in the brain. J Exp Med. 1992;176:1355-64.
44. Nagler-Anderson C, Bober A, Robinson M, Siskind G, Thorbecke G. Suppression of type II collagen-induced arthritis by intragastric administration of soluble type II collagen. Proc Natl Acad Sci U S A. 1986;83:7443-6.
45. Zhang ZJ, Davidson LE, Eisenbarth G, Weiner HL. Suppression of diabetes in nonobese diabetic mice by oral administration of porcine insulin. Proc Natl Acad Sci U S A. 1991;88:10252-6.
46. Lúdvíksson BR, Gray B, Strober W, Ehrhardt RO. Dysregulated intrathymic development in the IL-2-deficient mouse leads to colitis-inducing thymocytes. J Immunol. 1997;158:104-11.
47. Krämer S, Schimpl A, Hünig T. Immunopathology of interleukin (IL) 2-deficient mice: thymus dependence and suppression by thymus-dependent cells with an intact IL-2 gene. J Exp Med. 1995;182:1769-76.
48. Hollander GA, Simpson SJ, Mizoguchi E, Nichogiannopoulou A, She J, Gutierrez-Ramos JC, et al. Severe colitis in mice with aberrant thymic selection. Immunity 1995;3:27-38.
49. Sartor RB. Current concepts of the etiology and pathogenesis of ulcerative colitis and Crohn's disease. Gastroenterol Clin North Am. 1995;24:475-507.
50. Morris GP, Beck PL, Herridge MS, DePew WT, Szewczuk MR, Wallace JL. Hapten-induced model of colonie inflammation and ulceration in the rat colon. Gastroenterology. 1989;96:795-803.
51. + T cells. J Immunol. 1995;154: 1232-8.
52. Neurath MF, Fuss IJ, Pasparkis M, Alexopoulou L, Haralambous S, Meyer zum Buschenfelde KH, et al. Predominant pathogenic role of tumor necrosis factor alpha in experimental colitis in mice. Eur J Immunol. 1997;27:1743-50.
53. Weiner HL. Oral tolerance. Proc Natl Acad Sci U S A. 1994;91:10762-5.
54. Elson CO, Beagley KW, Sharmanov AT, Fujihashi K, Kiyono H, Tennyson GS, et al. Hapten-induced model of murine inflammatory bowel disease: mucosa immune responses and protection by tolerance. J Immunol. 1996; 157:2174-85.
55. + T cells. J Exp Med. 1996;183:2669-74.
56. 2 production by human synovial cells and dermal fibroblasts. J Exp Med. 1985;162:2163-8.
57. κ B abrogates established experimental colitis in mice. Nat Med. 1996;2:998-1004.
58. van Dulleman HM, van Deventer SJ, Hommes DW, Bijl HA, Jansen J, Tytgat GN. et al. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology. 1995;109:129-35.
59. Targan SR, Hanauer SB, van Deventer SJ, Mayer L, Prersent DH, Braakman T, et al. A short term study of chimeric monoclonal antibody cA2 to tumor necrosis factor-alpha for Crohn's disease. N Engl J Med. 1997;337: 1029-35.
60. Stack WA, Mann SD, Roy AJ, Heath P, Sopwith M, Freeman J, et al. Randomised controlled trial of CDP571 antibody to tumor necrosis factor-α in Crohn's disease. Lancet. 1997;349:521-4.
61. Firestein GS, Zvaifler NJ. Anticytokine therapy in rheumatoid arthritis [Editorial]. N Engl J Med. 1997;337:195-7.
62. van Deventer SJ, Elson CO, Fedorak RN. Multiple doses of intravenous interleukin 10 in steroid-refractory Crohn's disease. Crohn's Disease Study Group. Gastroenterology. 1997;113:383-9.